Get the Stockscreener App
0.6451
5.41%
-0.0369
Nexentis Technologies Inc stock is traded at $0.6451, with a volume of 38,523.
It is down -5.41% in the last 24 hours and down -52.91% over the past month.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
See More
Previous Close:
$0.682
Open:
$0.703
24h Volume:
38,523
Relative Volume:
0.02
Market Cap:
$937.55K
Revenue:
$2,000
Net Income/Loss:
$-12.72M
P/E Ratio:
-0.00898
EPS:
-71.8121
Net Cash Flow:
$-3.91M
1W Performance:
-24.77%
1M Performance:
-52.91%
6M Performance:
-83.75%
1Y Performance:
+0.00%
1-Day Range:
$0.6116
$0.71
1-Week Range:
$0.5994
$0.873
52-Week Range:
$0.5994
$23.80
Nexentis Technologies Inc Stock (NXTS) Company Profile
Name
Nexentis Technologies Inc
Sector
Industry
Phone
972544561349
Address
156 FIFTH AVENUE 10TH FLOOR, NEW YORK
Compare NXTS vs NTR, CF, CTVA, ICL, MOS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTS
Nexentis Technologies Inc
|
0.6451 | 937.55K | 2,000 | -12.72M | -3.91M | -71.81 |
NTR
Nutrien Ltd
|
71.26 | 34.01B | 27.83B | 2.42B | 2.21B | 4.9113 |
CF
Cf Industries Holdings Inc
|
120.85 | 18.29B | 7.41B | 2.12B | 1.62B | 11.13 |
CTVA
Corteva Inc
|
12.88 | 8.59B | 17.89B | 1.26B | 2.05B | 1.7029 |
ICL
Icl Group Ltd
|
4.97 | 6.41B | 7.41B | 314.00M | 220.88M | 0.202 |
MOS
Mosaic Company
|
18.82 | 5.98B | 12.43B | 70.90M | -489.30M | 0.1275 |
Nexentis Technologies Inc Stock (NXTS) Latest News
NXTS Stock Slides As Charts And Cash Flow Flash Caution - Timothy Sykes
NXTS Stock Compresses As Traders Study Key Levels - StocksToTrade
NXTS Stock Tests Volatility As Cash Cushion Buys Time - StocksToTrade
Nexentis Amends All Outstanding Warrants to Equity Classification for Nasdaq Compliance - Minichart
Warrant amendments at Nexentis (NXTS) add no shares upon exercise and do not extend their terms. - Stock Titan
NXTS Forecast — Price Target — Prediction for 2027 - TradingView
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board - GlobeNewswire Inc.
Nexentis Technologies Inc. (NXTS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nexentis Technologies Inc. (NXTS) stock price, news, quote and history - Yahoo Finance UK
Nexentis Technologies Faces Nasdaq Compliance and Delisting Risk - The Globe and Mail
Nexentis Faces Nasdaq Delisting Over Equity Shortfall - minichart.com.sg
Nexentis Technologies Faces Nasdaq Compliance and Delisting Risk - TipRanks
Nexentis Technologies Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
NXTS - Finviz
Nexentis Technologies Inc. (NASDAQ: NXTS) Share Price, NXTS Stock News, NXTS Share Price & Updates - Kalkine
Nexentis Technologies Inc. (NXTS) Rises 5.98% to $1.95, Approaching Key Resistance at $2.05Hedge Fund Favorites - Vinanet
Nexentis Technologies (NXTS) flags going concern after $17.7M loss and $6.3M impairment - Stock Titan
Nexentis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nexentis Technologies Inc. (NXTS) Rises 5.98% to $1.95, Approaching Key Resistance at $2.05Hedge Fund Favorites - vinanet.vn
Nexentis Technologies (NASDAQ: NXTS) changes auditors after prior going concern note - Stock Titan
Nexentis Technologies (NXTS) Gains 4% as Bullish Momentum Builds Toward Key $2.03 ResistanceInstitutional Volume - vinanet.vn
NXTS Q2 2025 Earnings: Loss of $0.18 Per Share Reported as Stock Climbs 10.32%Analyst Earnings Estimate - vinanet.vn
NXTS Q2 2025 Earnings: Reported Loss of -$0.18 Per Share, Yet Shares Jump 10.32%Financial Health Score - vinanet.vn
Nexentis subsidiary selects candidate for drug discovery program By Investing.com - Investing.com Canada
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign - globenewswire.com
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign - The Manila Times
Nexentis Technologies Inc. (NXTS) Q2 2025 Earnings: Loss and Stock Decline Reflect Ongoing ChallengesDividend Cut Risk - dars.gov.et
Nexentis Technologies Inc. (NXTS) Q2 2025 Earnings: Loss and Stock Decline Reflect Ongoing Challenges - dars.gov.et
Nexentis Technologies Inc. (NXTS) Q2 2025 Earnings: Loss and Stock Decline Reflect Ongoing Challenges - dars.gov.et
Nexentis Technologies Inc. Revenue Breakdown – NASDAQ:NXTS - TradingView
Nexentis Technologies (NXTS) Drops 7%: Key Support Level in FocusStraddle Setup - dars.gov.et
NXTS Q2 2025 Earnings: Wider-than-expected loss drives shares down 7.86%Earnings Season Outlook - vinanet.vn
Nexentis Technologies Inc. SEC Filing (Jul 20, 2026) - Stock Titan
NXTS Q2 2025 Earnings: Reported Loss of $0.18 per Share Amid Market SelloffAnalyst Drop Coverage - dars.gov.et
NXTS Q2 2025 Earnings: Reported Loss of $0.18 per Share Amid Market SelloffDownward Estimate Revision - vinanet.vn
Nexentis Technologies soars 156% before falling 46% after hours — here’s why NXTS stock is trending - MSN
Nexentis Technologies Inc. SEC Filing (Jul 16, 2026) - Stock Titan
Eun Young Lee holds 3.23% of Nexentis Technologies Inc. (NXTS) - Stock Titan
NXTS Q2 2025 Earnings: Wider-Than-Expected Loss Sends Shares LowerMargin Compression Risk - vinanet.vn
Nexentis Technologies files prospectus for 2.573M shares - scanx.trade
Nexentis Technologies registers to sell 2.57M shares of common stock for holders - TipRanks
Nexentis Technologies (NASDAQ: NXTS) refreshes $100M shelf and details MitoCareX deal - Stock Titan
Nexentis Technologies (NASDAQ: NXTS) registers 2.57M warrant shares for resale - Stock Titan
Nexentis Technologies Q2 2025 Earnings: Loss of -$0.18 Per Share Sends Stock Down 14.56%Earnings Power Value - vinanet.vn
Nexentis Technologies (NXTS) Slides 4.5% as Selling Pressure Tests Key Support at $3.46Double EMA - dars.gov.et
NXTS Q2 2025 Earnings: Net Loss of $0.18 Per Share as Stock Slips 3.6%Earnings Quality Score - dars.gov.et
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative - The Manila Times
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter - GlobeNewswire
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative - Barchart.com
NXTSNexentis Technologies Inc Earnings - Finviz
Nexentis Technologies Inc Stock (NXTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
32.54%
6.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):